The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

New study sheds light on how bacteria ‘vaccinate’ themselves with genetic material from dormant viruses
Pharma & Human Health

New study sheds light on how bacteria ‘vaccinate’ themselves with genetic material from dormant viruses

MAR 27, 2025
Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
Editor's Choice

Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation

MAR 25, 2025
PepsiCo to Acquire fast-growing prebiotic soda brand for $1.95 billion
Finance

PepsiCo to Acquire fast-growing prebiotic soda brand for $1.95 billion

MAR 21, 2025
Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 
Clinical & Manufacturing

Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 

MAR 7, 2025
Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
Editor's Choice

Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis

MAR 5, 2025
Synthetic microbiome therapy suppresses bacterial infection without antibiotics
Infectious Disease & AMR

Synthetic microbiome therapy suppresses bacterial infection without antibiotics

MAR 5, 2025
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
Finance

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

FEB 26, 2025
Scientists decode diet from stool DNA – no questions asked
Editor's Choice

Scientists decode diet from stool DNA – no questions asked

FEB 24, 2025
Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome
Pharma & Human Health

Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome

FEB 12, 2025
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Clinical & Manufacturing

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

JAN 27, 2025